Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-97c09c3f6bb46169676674f25613736c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-97c09c3f6bb46169676674f25613736c"/>
<resource>
<Composition>
<id value="composition-en-97c09c3f6bb46169676674f25613736c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-97c09c3f6bb46169676674f25613736c"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-97c09c3f6bb46169676674f25613736c</b></p><a name="composition-en-97c09c3f6bb46169676674f25613736c"> </a><a name="hccomposition-en-97c09c3f6bb46169676674f25613736c"> </a><a name="composition-en-97c09c3f6bb46169676674f25613736c-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1343/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - silodosin</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1343/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp97c09c3f6bb46169676674f25613736c"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - silodosin"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Silodosin Recordati is and what it is used for</li><li>What you need to know before you take Silodosin Recordati</li><li>How to take Silodosin Recordati</li><li>Possible side effects</li><li>How to store Silodosin Recordati</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What silodosin is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What silodosin is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Silodosin Recordati is</p><p>Silodosin Recordati belongs to a group of medicines called alpha1A-adrenoreceptor blockers. Silodosin Recordati is selective for the receptors located in the prostate, bladder and urethra. By blocking these receptors, it causes smooth muscle in these tissues to relax. This makes it easier for you to pass water and relieves your symptoms.</p><p>What Silodosin Recordati is used for</p><p>Silodosin Recordati is used in adult men to treat the urinary symptoms associated with benign enlargement of the prostate (prostatic hyperplasia), such as:</p><ul><li>difficulty in starting to pass water,</li><li>a feeling of not completely emptying the bladder,</li><li>a more frequent need to pass water, even at night.</li></ul></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take silodosin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take silodosin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Silodosin Recordati</p><p>if you are allergic to silodosin or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Silodosin Recordati</p><ul><li><p>If you are undergoing eye surgery because of cloudiness of the lens (cataract surgery), it is important that you immediately inform your eye specialist that you are using or have previously used Silodosin Recordati. This is because some patients treated with this kind of medicine experienced a loss of muscle tone in the iris (the coloured circular part of the eye) during such a surgery. The specialist can take appropriate precautions with respect to medicine and surgical techniques to be used. Ask your doctor whether or not you should postpone or temporarily stop taking Silodosin Recordati when undergoing cataract surgery.</p></li><li><p>If you have ever fainted or felt dizzy when suddenly standing up, please inform your doctor before taking Silodosin Recordati.<br/>Dizziness when standing up and occasionally fainting may occur when taking Silodosin Recordati, particularly when starting treatment or if you are taking other medicines that lower blood pressure. If this occurs, make sure you sit or lie down straight away until the symptoms have disappeared and inform your doctor as soon as possible (see also section Driving and using machines ).</p></li><li><p>If you have severe liver problems, you should not take Silodosin Recordati, as it was not tested in this condition.</p></li><li><p>If you have problems with your kidneys, please ask your doctor for advice.<br/>If you have moderate kidney problems, your doctor will start Silodosin Recordati with caution and possibly with a lower dose (see section 3 Dose ).<br/>If you have severe kidney problems, you should not take Silodosin Recordati.</p></li><li><p>Since a benign enlargement of the prostate and prostate cancer may present the same symptoms, your doctor will check you for prostate cancer before starting treatment with Silodosin Recordati. Silodosin Recordati does not treat prostate cancer.</p></li><li><p>The treatment with Silodosin Recordati may lead to an abnormal ejaculation (decrease in the amount of semen released during sex) that may temporarily affect male fertility. This effect disappears after discontinuation of Silodosin Recordati. Please inform your doctor if you are planning to have children.</p></li></ul><p>Children and adolescents</p><p>Do not give this medicine to children and adolescents below 18 years since there is no relevant indication for this age group.</p><p>Other medicines and Silodosin Recordati</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor in particular, if you take:</p><ul><li>medicines which lower blood pressure (in particular, medicines called alpha1-blockers, such as prazosin or doxazosin) as there may be the potential risk that the effect of these medicines is increased whilst taking Silodosin Recordati.</li><li>antifungal medicines (such as ketoconazole or itraconazole), medicines used for HIV-AIDS (such as ritonavir) or medicines used after transplants to prevent organ rejection (such as cyclosporin) because these medicines can increase the blood concentration of Silodosin Recordati.</li><li>medicines used for treating problems in getting or keeping an erection (such as sildenafil or tadalafil), since the concomitant use with Silodosin Recordati might lead to a slight decrease in blood pressure.</li><li>medicines for epilepsy or rifampicin (a medicine to treat tubercolosis), since the effect of Silodosin Recordati may be reduced.</li></ul><p>Pregnancy and breast-feeding</p><p>Silodosin Recordati is not intended for use by women.</p><p>Fertilty</p><p>Silodosin Recordati may reduce the amount of sperm, and so could temporarily affect your ability to father a child. If you are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Driving and using machines</p><p>Do not drive or operate machines if you feel faint, dizzy, drowsy or have blurred vision.</p><p>Silodosin Recordati contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take silodosin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take silodosin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is one capsule of Silodosin Recordati 8 mg per day by oral administration.</p><p>Take the capsule always with food, preferably at the same time every day. Do not break or chew the capsule, but swallow it whole, preferably with a glass of water.</p><p>Patients with kidney problems<br/>If you have moderate kidney problems, your doctor may prescribe a different dose. For this purpose Silodosin Recordati 4 mg hard capsules are available.</p><p>If you take more Silodosin Recordati than you should</p><p>If you have taken more than one capsule, inform your doctor as soon as possible. If you become dizzy or feel weak, tell your doctor straight away.</p><p>If you forget to take Silodosin Recordati</p><p>You may take your capsule later the same day if you have forgotten to take it earlier. If it is almost time for the next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten capsule.</p><p>If you stop taking Silodosin Recordati</p><p>If you stop treatment, your symptoms may re-appear.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact your doctor immediately if you notice any of the following allergic reactions: swelling of the face or throat, difficulty in breathing, feeling faint, itchy skin or hives since the consequences could become serious.</p><p>The most common side effect is a decrease in the amount of semen released during sex. This effect disappears after discontinuation of Silodosin Recordati. Please inform your doctor if you are planning to have children.</p><p>Dizziness, including dizziness when standing up, and occasionally fainting, may occur. If you do feel weak or dizzy, make sure you sit or lie down straight away until the symptoms have disappeared. If dizziness when standing up or fainting occurs, please inform your doctor as soon as possible.</p><p>Silodosin Recordati may cause complications during a cataract surgery (eye surgery because of cloudiness of the lens, see section Warnings and precautions ). It is important that you immediately inform your eye specialist if you are using or have previously used Silodosin Recordati.</p><p>The possible side effects are listed below:</p><p>Very common side effects (may affect more than 1 in 10 people)</p><ul><li>Abnormal ejaculation (less or no noticeable semen is released during sex, see section Warnings and precautions )</li></ul><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li>Dizziness, including dizziness when standing up (see also above, in this section)</li><li>Runny or blocked nose</li><li>Diarrhoea</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>Decreased sexual drive</li><li>Nausea</li><li>Dry mouth</li><li>Difficulties in getting or keeping an erection</li><li>Faster heart rate</li><li>Symptoms of allergic reaction affecting the skin like rash, itching, hives and rash caused by a medicine</li><li>Abnormal results of liver function tests</li><li>Low blood pressure</li></ul><p>Rare side effects (may affect up to 1 in 1 000 people)</p><ul><li>Fast or irregular heart beats (called palpitations)</li><li>Fainting/ Loss of consciousness</li></ul><p>Very rare side effects (may affect up to 1 in 10 000 people)</p><ul><li>Other allergic reactions with swelling of the face or throat</li></ul><p>Not known (frequency cannot be estimated from the available data)</p><ul><li>Floppy pupil during cataract surgery (see also above, in this section)</li></ul><p>If you feel that your sexual life is affected, please tell your doctor.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store silodosin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store silodosin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30 C. Store in the original package in order to protect from light and moisture.</p><p>Do not use this medicine if you notice that is damaged or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Silodosin Recordati contains</p><p>Silodosin Recordati 8 mg The active substance is silodosin. Each capsule contains 8 mg of silodosin.</p><p>The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium laurilsulfate, gelatin and titanium dioxide (E171). Please refer to section 2 Silodosin Recordati contains sodium .</p><p>Silodosin Recordati 4 mg The active substance is silodosin. Each capsule contains 4 mg of silodosin.</p><p>The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium laurilsulfate gelatin, titanium dioxide (E171), and yellow iron oxide (E172). Please refer to section 2 Silodosin Recordati contains sodium .</p><p>What Silodosin Recordati looks like and contents of the pack</p><p>Silodosin Recordati 8 mg are white, opaque, hard gelatin capsules, size 0 (approximately 21.7 x 7.6 mm).</p><p>Silodosin Recordati 4 mg are yellow, opaque, hard gelatin capsules, size 3 (approximately 15.9 x 5.8 mm).</p><p>Silodosin Recordati is available in packs containing 10, 20, 30, 50, 90, 100 capsules. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>Recordati Ireland Ltd. Raheens East Ringaskiddy Co. Cork Ireland</p><p>Manufacturer</p><p>Recordati Industria Chimica e Farmaceutica S.p.A. Via Matteo Civitali 1 20148 Milan Italy</p><p>Laboratoires Bouchara-Recordati Parc M catronic 03410 Saint Victor France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Recordati Ireland Ltd. T l/Tel: + 353 21 4379Lietuva Recordati Ireland Ltd. Tel: + 353 21 4379<br/>Recordati Ireland Ltd. .: + 353 21 4379Luxembourg/Luxemburg Recordati Ireland Ltd. T l/Tel: + 353 21 4379 esk republika Herbacos Recordati s.r.o. Tel: + 420 466 741 Magyarorsz g Recordati Ireland Ltd. Tel: + 353 21 4379Danmark Recordati Ireland Ltd. Tlf: + 353 21 4379Malta Recordati Ireland Ltd. Tel: + 353 21 4379Deutschland Recordati Pharma GmbH Tel: + 49 731 70Nederland Recordati Ireland Ltd. Tel: + 353 21 4379Eesti Recordati Ireland Ltd. Tel: + 353 21 4379Norge Recordati Ireland Ltd. Tlf: + 353 21 4379<br/>Recordati Hellas Pharmaceuticals A.E. : + 30 210-6773 sterreich Recordati Ireland Ltd. Tel: + 353 21 4379Espa a Casen Recordati, S.L. Tel: + 34 91 659 15 Polska Recordati Polska sp. z o.o. Tel: + 48 22 206 84 France Laboratoires BOUCHARA-RECORDATI T l: + 33 1 45 19 10 Portugal Jaba Recordati, S.A. Tel: + 351 21 432 95 Hrvatska Recordati Ireland Ltd. Tel: + 353 21 4379Rom nia Recordati Rom nia S.R.L. Tel: + 40 21 667 17 Ireland Recordati Ireland Ltd. Tel: + 353 21 4379Slovenija Recordati Ireland Ltd. Tel: + 353 21 4379 sland Recordati Ireland Ltd. S mi: + 353 21 4379Slovensk republika Herbacos Recordati s.r.o. Tel: + 420 466 741 Italia Recordati Industria Chimica e Farmaceutica S.p.A. Tel: + 39 02 487Suomi/Finland Recordati Ireland Ltd. Puh/Tel: + 353 21 4379<br/>Recordati Ireland Ltd. : + + 353 21 4379Sverige Recordati Ireland Ltd. Tel: + 353 21 4379Latvija Recordati Ireland Ltd. Tel: + 353 21 4379United Kingdom (Northern Ireland) Recordati Ireland Ltd. Tel: + 353 21 4379This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp97c09c3f6bb46169676674f25613736c"/>
<resource>
<MedicinalProductDefinition>
<id value="mp97c09c3f6bb46169676674f25613736c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp97c09c3f6bb46169676674f25613736c"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp97c09c3f6bb46169676674f25613736c</b></p><a name="mp97c09c3f6bb46169676674f25613736c"> </a><a name="hcmp97c09c3f6bb46169676674f25613736c"> </a><a name="mp97c09c3f6bb46169676674f25613736c-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1343/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Silodosin Recordati 4 mg hard capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1343/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Silodosin Recordati 4 mg hard capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
